Figure 5 | Scientific Reports

Figure 5

From: Tumor-targeted delivery of a C-terminally truncated FADD (N-FADD) significantly suppresses the B16F10 melanoma via enhancing apoptosis

Figure 5

VNP-pN-N-FADD delayed tumor growth and enhanced survival time in B16F10 mice model.

(A) Tumor growth curves of groups as indicated. B16F10 tumor mice per group (n = 10 mice) were injected i.p. with 2 × 105 cfu of VNP, VNP-pN, VNP-pN-FADD and VNP-pN-N-FADD or with PBS at day 7. Tumor volumes among different groups were compared. Data are presented as mean ± SD. *P < 0.05 for VNP-pN-FADD versus VNP or VNP-pN; **P < 0.01 for VNP-pN-N-FADD versus VNP-pN-FADD; ***P < 0.001 for VNP-pN-N-FADD versus VNP or VNP-pN. (B) Kaplan-Meier survival curves of mice bearing B16F10 melanomas. Data were analyzed by the log-rank test. *P < 0.05 for VNP-pN-N-FADD versus PBS, VNP, VNP-pN and VNP-pN-FADD. (C,D) Representative therapeutic efficacy of the recombinant VNP strains for melanoma therapy. (E,F) Tumor doubling time and growth delay. Data are presented as mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001, (n = 10 mice). (G) Immunofluorescence staining of FADD (stained red), the representative images (100×) revealing FADD or N-FADD expression in B16F10 tumor tissue treated with PBS, VNP, VNP-pN, VNP-pN-FADD and VNP-pN-N-FADD.

Back to article page